Fig. 10From: Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapyDrug sensitivity analysis of ICOS. The expression of ICOS was associated with the sensitivity of pipobroman (A), bendamustine (B), cordycepin (C), entinostat (D), nelarabine (E), XK-469 (F), dabrafenib (G), temsirolimus (H), panobinostat (I), (+)-JQ-1 (J), thiotepa (K), triethylenemelamine (L), vemurafenib (M), cisplatin (N), dasatinib (O), and LY-294,002 (P)Back to article page